Alnylam Pharmaceuticals, Inc.

NasdaqGS:ALNY Stok Raporu

Piyasa değeri: US$34.9b

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Alnylam Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 3/4

Alnylam Pharmaceuticals' CEO'su Yvonne Greenstreet, Jan2022 tarihinde atandı, in görev süresi 2.75 yıldır. in toplam yıllık tazminatı $ 8.90M olup, şirket hissesi ve opsiyonları dahil olmak üzere 11% maaş ve 89% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.039% ine doğrudan sahiptir ve bu hisseler $ 13.78M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.3 yıl ve 8.9 yıldır.

Anahtar bilgiler

Yvonne Greenstreet

İcra Kurulu Başkanı

US$8.9m

Toplam tazminat

CEO maaş yüzdesi11.0%
CEO görev süresi2.8yrs
CEO sahipliği0.04%
Yönetim ortalama görev süresi3.3yrs
Yönetim Kurulu ortalama görev süresi8.9yrs

Son yönetim güncellemeleri

Recent updates

Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 49%?

Sep 12
Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 49%?

Alnylam: HELIOS-B Success Priced In Already

Aug 30

Analysts Are Upgrading Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) After Its Latest Results

Aug 04
Analysts Are Upgrading Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) After Its Latest Results

Broker Revenue Forecasts For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Are Surging Higher

Aug 02
Broker Revenue Forecasts For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Are Surging Higher

RNAi: Winning In The Clinic, Now For The Market

Jun 25

Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation

Jun 03

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking

Mar 19
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking

Is Alnylam's HELIOS-B Delay A Red Flag?

Mar 10

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think

Feb 18
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think

Alnylam's Huge Opportunity

Jan 12

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Out Of Tune With Revenues

Dec 18
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Out Of Tune With Revenues

Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares

Jun 23
Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares

Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Weighed On By Its Debt Load?

Oct 25
Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Weighed On By Its Debt Load?

Alnylam gets FDA nod for expanded use of rare disease drug Oxlumo

Oct 07

Alnylam: Onpattro's Position In The ATTR Amyloidosis Cardiomyopathy Market

Sep 26

Alnylam RNAi therapy for rare protein disorder gets EU approval

Sep 20

Alnylam to offer $900M convertible senior notes

Sep 12

CEO Tazminat Analizi

Yvonne Greenstreet'un ücretlendirmesi Alnylam Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$73m

Mar 31 2024n/an/a

-US$332m

Dec 31 2023US$9mUS$976k

-US$440m

Sep 30 2023n/an/a

-US$510m

Jun 30 2023n/an/a

-US$1b

Mar 31 2023n/an/a

-US$1b

Dec 31 2022US$5mUS$850k

-US$1b

Sep 30 2022n/an/a

-US$1b

Jun 30 2022n/an/a

-US$981m

Mar 31 2022n/an/a

-US$893m

Dec 31 2021US$9mUS$619k

-US$853m

Sep 30 2021n/an/a

-US$838m

Jun 30 2021n/an/a

-US$887m

Mar 31 2021n/an/a

-US$876m

Dec 31 2020US$3mUS$622k

-US$858m

Sep 30 2020n/an/a

-US$891m

Jun 30 2020n/an/a

-US$846m

Mar 31 2020n/an/a

-US$886m

Dec 31 2019US$3mUS$571k

-US$886m

Sep 30 2019n/an/a

-US$821m

Jun 30 2019n/an/a

-US$858m

Mar 31 2019n/an/a

-US$802m

Dec 31 2018US$3mUS$540k

-US$761m

Sep 30 2018n/an/a

-US$692m

Jun 30 2018n/an/a

-US$570m

Mar 31 2018n/an/a

-US$525m

Dec 31 2017US$985kUS$504k

-US$491m

Tazminat ve Piyasa: Yvonne 'nin toplam tazminatı ($USD 8.90M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 13.04M ).

Tazminat ve Kazançlar: Yvonne şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Yvonne Greenstreet (61 yo)

2.8yrs

Görev süresi

US$8,895,670

Tazminat

Dr. Yvonne L. Greenstreet, MBChB, MBA, is Chief Executive Officer at Alnylam Pharmaceuticals, Inc. since January 01, 2022. Dr. Greenstreet joined the Alnylam Pharmaceuticals, Inc. on September 19, 2016. Sh...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Yvonne Greenstreet
CEO & Director2.8yrsUS$8.90m0.039%
$ 13.6m
Jeffrey Poulton
CFO & Executive VP5.2yrsUS$3.22m0.017%
$ 5.8m
Akshay Vaishnaw
Chief Innovation Officer & Member of the Scientific Advisory Boardless than a yearUS$3.32m0.018%
$ 6.3m
Pushkal Garg
Chief Medical Officer10yrsUS$3.23m0.0090%
$ 3.1m
Tolga Tanguler
Executive VP & Chief Commercial Officer3.8yrsUS$2.87m0.0054%
$ 1.9m
Timothy Maines
Chief Technical Operations & Quality Officer1.8yrsVeri yokVeri yok
Kevin Fitzgerald
Senior VP5.4yrsVeri yok0.010%
$ 3.6m
Christine Lindenboom
Senior VP of Investor Relations & Corporate Communicationsno dataVeri yokVeri yok
Piyush Sharma
Chief Ethics & Compliance Officer2.1yrsVeri yokVeri yok
Evan Lippman
Chief Corporate Development & Strategy Officer2.1yrsVeri yokVeri yok
Kelley Boucher
Chief Human Resource Officer5.4yrsVeri yokVeri yok
Muthiah Manoharan
Senior VP of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Boardno dataVeri yokVeri yok

3.3yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: ALNY 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.3 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Yvonne Greenstreet
CEO & Director3yrsUS$8.90m0.039%
$ 13.6m
Akshay Vaishnaw
Chief Innovation Officer & Member of the Scientific Advisory Boardno dataUS$3.32m0.018%
$ 6.3m
Muthiah Manoharan
Senior VP of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Board9yrsVeri yokVeri yok
Peter Kellogg
Independent Director1.6yrsUS$658.72k0%
$ 0
Paul Schimmel
Member of the Scientific Advisory Boardno dataUS$516.04kVeri yok
David E. Pyott
Independent Director8.8yrsUS$477.21k0.022%
$ 7.6m
Phillip Sharp
Co-Founder22.3yrsUS$502.21k0.21%
$ 72.5m
Amy W. Schulman
Independent Chair of the Board & Lead Independent Director10.3yrsUS$531.36k0.0066%
$ 2.3m
Markus Stoffel
Member of Scientific Advisory Boardno dataVeri yokVeri yok
David Bartel
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Dennis Ausiello
Member of the Scientific Advisory Board & Independent Director12.5yrsUS$477.21k0.0028%
$ 986.6k
Colleen Reitan
Independent Director6.3yrsUS$489.15k0%
$ 0

8.9yrs

Ortalama Görev Süresi

69.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ALNY 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.9 yıldır).